Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
![Imatge de Publicacions](/sites/default/files/styles/3_1_small/public/2022-11/Portada_publicacions-petita_0.jpg?h=c6980913&itok=oZMso2V6)
Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire.
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection.
Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody.
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.
Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection.